Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis

Advanced Drug Delivery Reviews

Volumn 56, Issue 8, 2004, Pages 1205-1217

  Paulos, Chrystal M ^a   Turk, Mary Jo ^b   Breur, Gert J ^c   Low, Philip S ^a  

^a PURDUE UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

Arthritis therapy; Elimination of activated macrophages; Folate receptor targeting; Folate conjugated drug targeting; Immunotherapeutic agents; Inflammation mediators

Indexed keywords

AGENTS; BONE; CARTILAGE; CELLS; DRUG DOSAGE; IMAGING SYSTEMS; IMMUNOLOGY; JOINTS (ANATOMY);

AUTOIMMUNE DISEASE; FOLATE RECEPTOR (FR); INFLAMMATION; THERAPEUTIC AGENTS;

BIOMEDICAL ENGINEERING;

CELECOXIB; EDOXUDINE; ETANERCEPT; FLUORESCEIN ISOTHIOCYANATE; FOLATE RECEPTOR; FOLIC ACID; INDIUM 111; INFLIXIMAB; KEYHOLE LIMPET HEMOCYANIN; MEMBRANE RECEPTOR; METHOTREXATE; PENTETIC ACID; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROFECOXIB; TECHNETIUM 99M; UNCLASSIFIED DRUG;

DRUG DISTRIBUTION; DRUG TARGETING; HUMAN; LEUKOCYTE; MACROPHAGE ACTIVATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS;

EID: 1942503257     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2004.01.012     Document Type: Article

References (64)

1. Lawrence R.C., Helmick C.G., Arnett F.C., Deyo R.A., Felson D.T., Giannini E.H., Heyes S.P., Hirsh K., Hochberg M.C., Hunder G.G., Liang M.H., Pillemer S.R., Steen V.V., Wolfe F. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 41:1998;778-799.
2. Silman A.J., Hochberg M.C. Epidemiology of the Rheumatic Diseases. 1994;Oxford Univ. Press, Oxford.
3. Scott D.L., Shipley M., Davison A., Edwards S., Symmons D.P., Woolf A.D. The clinical management of rheumatoid arthritis and osteoarthritis strategies for improving clinical effectiveness. Br. J. Rheumatol. 37:1998;546-554.
4. Wolfe F., Hawley D.J. The longterm outcomes of rheumatoid arthritis: work disability: a prospective 18 year study of 823 patients. J. Rheumatol. 25:1998;2108-2117.
5. Yelin E., Callahan C.F. The economic costs and social physiological impact on musculoskeletal conditions. Arthritis Rheumatol. 38:1995;1351-1362.
6. Yelin E. The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J. Rheumatol., Suppl. 44:1996;47-51.
7. Bloom B.S. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am. J. Med. 84:1998;20-24.
8. Greene J.M., Winickoff R.N. Cost-conscious prescribing of nonsteroidal anti-inflammatory drugs for adults with arthritis. A review and suggestions. Arch. Intern. Med. 152:1992;1995-2002.
9. Kinne R.W., Brauer R., Stuhlmuller B., Palombo-Kinne E., Burmester G.R.et al. Macrophages in rheumatoid arthritis. Arthritis Res. 2:2000;189-202.
10. Yanni G., Whelan A., Feighery C., Bresnihan B. Synovial tissue macrophages and joint erosion in rheumatoid arthritis. Ann. Rheum. Dis. 53:1994;39-44.
11. Tak P.P., Smeets T.J., Daha R.R., Kluin P.M., Meijers K.A., Brand R., Meinders A.E., Breedveld F.C. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum. 40:1997;217-225.
12. Mulherin D., Fitzgerald O., Bresnihan B. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum. 39:1996;115-124.
13. Kmiec Z. Cooperation of liver cells in health and disease. Adv Anat Embryol Cell Biol; 161 (2001) III-XIII, 1-151.
14. Bresnihan B. Pathogenesis of joint damage in rheumatoid arthritis. J. Rheumatol. 26:1999;717-719.
15. Burmester G.R., Stuhlmuller B., Keyszer G., Kinne R.W. Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis? Arthritis Rheum. 40:1997;5-18.
16. Smolen J.S., Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat. Rev., Drug Discov. 2:2003;473-488.
17. Goldenberg M.M. Celebrex, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. Clin. Ther. 21:1999;1497-1513.
18. Richard-Miceli C., Dougados M. Tumour necrosis factor-alpha blockers in rheumatoid arthritis: review of the clinical experience. BioDrugs. 15:2001;251-259.
19. Schiff M.H. Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis. Ann. Rheum. Dis. 59(Suppl. 1):2000;i103-i108.
20. Weinblatt M.E., Kremer J.M., Coblyn J.S., Maier A.L., Helfgolt S.M., Morrell M., Byrne V.M., Kaymakcian M.V., Strand V. Pharmacokinetics, safety and efficacy combination of methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum. 42:1999;1322-1327.
21. Weinblatt M.E., Kremer J.M., Bankhurst A.D., Bulpitt J.J., Fleishmann R.M., Fox R.I., Jackson C.G., Lange M., Burge D.J. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340:1999;253-259.
22. Maini R.V., Breedveld F.C., Kalden J.R., Smolen J.S., Davis D., Macfarlane J.D., Antoni C., Leeb B., Elliott M.J., Woody J.N., Schaible T.F., Feldman M. Therpeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor and monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41:1998;1552-1563.
23. Lukina G.V., Sigidin Ia A., Skurkovich S.V., Skurkovich B.S. Double-blind trial of the effectiveness of antibodies to interferon-gamma and tumor necrosis factor-alpha in rheumatoid arthritis (preliminary results). Ter. Arkh. 73:2001;12-15.
24. Louie S.G., Park B., Yoon H. Biological response modifiers in the management of rheumatoid arthritis. Am. J. Health-Syst. Pharm. 60:2003;346-355.
25. Barthel H.R., Burmester G.R. Specific drugs for a complex disease: can there be a magic bullet against rheumatoid arthritis? Ann. Rheum. Dis. 54:1995;948-950.
26. Sokka T.M., Kaarela K., Mottonen T.T., Hannonen P. Conventional monotherapy compared to a "sawtooth" treatment strategy in the radiographic progression of rheumatoid arthritis over the first eight years. Clin. Exp. Rheumatol. 17:1999;527-532.
27. Sokka T.M., Kautiainen H.J., Hannonen P.J. A retrospective study of treating RA patients with various combinations of slow-acting antirheumatic drugs in a county hospital. Scand. J. Rheumatol. 26:1997;440-443.
28. Hidaka T., Suzuki K., Kawakami M., Okada M., Kataharada K., Shinohara T., Takamizawa-Matsumoto M., Ohsuzu F. Dynamic changes in cytokine levels in serum and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis. J. Clin. Apher. 16:2001;74-81.
29. Hidaka T., Suzuki K., Matsuki Y., Takamizawa-Matsumoto M., Kataharada K., Ishizuka T., Kawakami M., Nakamura H. Filtration leukocytapheresis therapy in rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 42:1999;431-437.
30. Van Rooijen N. The liposome-mediated macrophage 'suicide' technique. J. Immunol. Methods. 124:1989;1-6.
31. Richards P.J., Williams A.S., Goodfellow R.M., Williams B.D. Liposomal clodronate eliminates synovial macrophages, reduces inflammation and ameliorates joint destruction in antigen-induced arthritis. Rheumatology (Oxford). 38:1999;818-825.
32. Richards P.J., Williams B.D., Williams A.S. Suppression of chronic streptococcal cell wall-induced arthritis in Lewis rats by liposomal clodronate. Rheumatology (Oxford). 40:2001;978-987.
33. van Rooijen N., van Kesteren-Hendrikx E. Clodronate liposomes: perspectives in research and therapeutics. J. Liposome Res. 12:2002;81-94.
34. Valleala H., Laitinen K., Pylkkanen L., Konttinen Y.T., Friman C. Clinical and biochemical response to single infusion of clodronate in active rheumatoid arthritis - a double blind placebo controlled study. Inflamm. Res. 50:2001;598-601.
35. Paterson A.H. The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases. Cancer. 88(12 Suppl.):2000;3038-3046.
36. Watts N.T. Treatment of osteoporosis with bisphosphonates. Rheum. Dis. Clin. North Am. 27:2001;197-214.
37. Knighton D.R., Fiegel V.D. Macrophage-derived growth factors in wound healing: regulation of growth factor production by the oxygen microenvironment. Am. Rev. Respir. Dis. 140:1989;1108-1111.
38. Knighton D.R., Fiegel V.D. The macrophages: effector cell wound repair. Prog. Clin. Biol. Res. 299:1989;217-226.
39. van Rooijen N., Kors N. Effects of intracellular diphosphonates on cells of the mononuclear phagocyte system: in vivo effects of liposome-encapsulated diphosphonates on different macrophage subpopulations in the spleen. Calcif. Tissue Int. 45:1989;153-156.
40. Turk M.J., Breur G.J., Widmer W.R., Paulos C.M., Xu L.C., Grote L.A., Low P.S. Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis. Arthritis Rheum. 46:2002;1947-1955.
41. Salter D.N., Scott K.J., Slade H., Andrews P. The preparation and properties of folate-binding protein from cow's milk. Biochem. J. 193:1981;469-476.
42. Selhub J., Ahmad O., Rosenberg I.H. Preparation and use of affinity columns with bovine milk folate-binding protein (FBP) covalently linked to Sepharose 4B. Methods Enzymol. 66:1980;686-690.
43. Kamen B.A., Smith A.K., Anderson R.G. The folate receptor works in tandem with a probenecid-sensitive carrier in MA104 cells in vitro. J. Clin. Invest. 87:1991;1442-1449.
44. Turek J.J., Leamon C.P., Low P.S. Endocytosis of folate-protein conjugates: ultrastructural localization in KB cells. J. Cell. Sci. 106(Pt 1):1993;423-430.
45. Leamon C.P., Low P.S. Membrane folate-binding proteins are responsible for folate-protein conjugate endocytosis into cultured cells. Biochem. J. 291(Pt 3):1993;855-860.
46. Leamon C.P., Low P.S. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc. Natl. Acad. Sci. U. S. A. 88:1991;5572-5576.
47. Antony A.C. The biological chemistry of folate receptors. Blood. 79:1992;2807-2820.
48. Ross J.F., Chaudhuri P.K., Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer. 73:1994;2432-2443.
49. Kennedy M.D., Jallad K.N., Lu J., Low P.S., Ben-Amotz D. Evaluation of folate conjugate uptake and transport by the choroid plexus of mice. Pharm. Res. 20:2003;714-719.
50. Shen F., Ross J.F., Wang X., Ratnam M. Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry. 33:1994;1209-1215.
51. Shen F., Wu M., Ross J.F., Miller D., Ratnam M. Folate receptor type gamma is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification: protein characterization and cell type specificity. Biochemistry. 34:1995;5660.
52. Reddy J.A., Haneline L.S., Srour E.F., Antony A.C., Clapp W.D., Low P.S. Expression and functional characterization of the beta-isoform of the folate receptor on CD34(+) cells. Blood. 93:1999;3940-3948.
53. Ross J.F., Wang H., Behm F.G., Mathew P., Wu M., Booth R., Ratnam M. Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer. 85:1999;348-357.
54. Nakashima-Matsushita N., Homma T., Yu S., Matsuda T., Sunahara N., Nakamura T., Tsukano M., Ratnam M., Matsuyama T. Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum. 42:1999;1609-1616.
55. Leamon C.P., Parker M.A., Vlahov I.R., Xu L.C., Reddy J.A., Vetzel M., Douglas N.et al. Synthesis and biological evaluation of EC20: a new folate-derived, (99 m)Tc-based radiopharmaceutical. Bioconjug. Chem. 13:2002;1200-1210.
56. Schneider R., Laxer R.M. Systemic onset juvenile rheumatoid arthritis. Bailliere's Clin. Rheumatol. 12:1998;245-271.
57. Campbell D.A., Edwards N.L. Multicentric reticulohistiocytosis: systemic macrophage disorder. Bailliere's Clin. Rheumatol. 5:1991;301-319.
58. Mau W., Zeidler H. Follow-up and prognosis in chronic polyarthritis. Versicher.Med. 51:1991;115-121.
59. 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J. Nucl. Med. 44:2003;700-707.
60. Lu Y., Low P.S. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol. Immunother. 51:2002;153-162.
61. Fletcher D.S., Widmer W.R., Luell S., Christen A., Orevillo C., Shah S., Visco D. Therapeutic administration of a selective inhibitor of nitric oxide synthase does not ameliorate the chronic inflammation and tissue damage associated with adjuvant-induced arthritis in rats. J. Pharmacol. Exp. Ther. 284:1998;714-721.
62. van Roon J.A., van Vuuren A.J., Wijngaarden S., Jacobs K.M., Bijlsma J.W., Lafeber F.P., Thepen T., van de Winkel J.G. Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fcγ Receptor 1-directed immunotoxin. Arthritis Rheum. 48:2003;1229-1238.
63. Zubay Fife R. Methotrexate use in juvenile rheumatoid arthritis. Orthop. Nurs. 12:1993;32-36.
64. Reddy J.A., Low P.S. Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit. Rev. Ther. Drug Carr. Syst. 6:1998;587-627.